search icon

    Market Snapshot

    • S&P Futures

      3,809.5

    • Dow Futures

      30,868

    • Nasdaq Futures

      11,633.25

    blog search icon

    Apellis Pharmaceuticals, Inc.

    (NASDAQ:APLS)

    $45.22

    $0.03

    0.07%

    Apellis Pharmaceuticals, Inc. Chart

    APLS Stock Price Today

    Apellis Pharmaceuticals, Inc. (APLS) stock rallied over 0.07% intraday to trade at $45.22 a share on NASDAQ. The stock opened with a gain of 2.82% at $44.15 and touched an intraday high of $45.97, rising 0.07% against the last close of $45.19. The stock went to a low of $43.59 during the session.

    Stock Snapshot

    $45.19

    Prev. Close

    4.89 Billion

    Market Cap

    $43.59

    Day Low

    $44.15

    Open

    98.07 Million

    Number of Shares

    $45.97

    Day High

    -

    P/E ratio

    -8.02

    EPS (TTM)

    7.17

    Cash Flow per Share

    10.15

    Free Float in %

    -0.66

    Book Value

    709,601

    Volume

    Apellis Pharmaceuticals, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-06-30$44.15$45.97$43.59$45.22683,229
    2022-06-29$43.98$45.23$43.7$45.19530,900
    2022-06-28$46.5$46.78$44.32$44.38797,200
    2022-06-27$46.04$47.07$45.56$46.39653,400
    2022-06-24$47$47.94$45.1$46.262,278,500
    2022-06-23$44.17$47.02$43.85$471,031,500
    2022-06-22$42.61$45.19$42.52$43.981,025,100
    2022-06-21$44.79$45.805$43.81$43.861,017,900
    2022-06-17$43.81$45$42.96$44.141,524,000
    2022-06-16$40.3$42.95$40.3$42.87926,800

    Contact Details

    100 Fifth Avenue
    Waltham, MA 02451
    United States

    Webiste:APLS

    617 977 5700

    Company Information

    Employees-

    Beta1.48

    Sales or Revenue66.56 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

    Frequently Asked Questions

    icon

    What is the current Apellis Pharmaceuticals, Inc. (APLS) stock price?

    Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock price is $45.22 as of the last check on Thursday, June 30. During the trading session, APLS stock reached the peak price of $45.97 while $43.59 was the lowest point it dropped to.

    icon

    APLS's industry and sector of operation?

    The NASDAQ listed APLS is part of Biotechnology industry that operates in the broader Health Care sector. Apellis Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

    icon

    Who are the executives of APLS?

    Mr. Alec Machiels J.D., MBA
    Co-Founder & Independent Director
    Mr. Timothy E. Sullivan
    Chief Financial Officer
    Dr. Cedric Francois M.D., Ph.D.
    Co-Founder, Pres, CEO & Director
    Dr. Pascal Deschatelets Ph.D.
    Co-Founder & Chief Scientific Officer

    icon

    What is the APLS stock price today?

    APLS stock traded closed the last session at $45.22, which is $0.03 or 0.07% lower than its previous close of $45.19. APLS's current trading price is 64.44% lower than its 52-week high of $73.00 where as its distance from 52-week low of 27.50% is -38.05%.

    icon

    How many employees does APLS have?

    Number of APLS employees currently stands at -. APLS operates from 100 Fifth Avenue, Waltham, MA 02451, United States.

    icon

    Link for APLS official website?

    Official Webiste of $APLS is: https://www.apellis.com

    icon

    How do I contact APLS?

    APLS could be contacted at APLS operates from 100 Fifth Avenue, Waltham, MA 02451, United States, or at phone #617 977 5700 and can also be accessed through its website.

    icon

    How many shares of APLS are traded daily?

    APLS stock volume for the day was 709,601 shares while in the previous session number of APLS shares traded was 683,229 . The average number of APLS shares traded daily for last 3 months was 1.03 Million.

    icon

    How much did APLS change today?

    The percentage change in APLS stock occurred in the recent session was 0.07% while the dollar amount for the price change in APLS stock was $0.03.

    icon

    What price range APLS stock been trading in?

    In the recent session, the day high for APLS stock was $45.97 while the low for APLS stock touched on the day was $43.59.

    icon

    What is the market cap of APLS currently?

    The market value of APLS currently stands at 4.89 Billion with its latest stock price at $45.22 and 98.07 Million of its shares outstanding.